OCTOBER 1–3
Salamander Washington DC
Program Committee

Chair: Primo N. Lara, Jr., MD
UC Davis Comprehensive Cancer Center

Edward Chu, MD, MMS
Montefiore Einstein
Comprehensive Cancer Center

Hannah Hazard-Jenkins, MD
WVU Cancer Institute

Matthew Huesser, MBA, DBA
Sidney Kimmel Cancer Center at Jefferson Health

Kelvin Lee, MD
Indiana University Melvin and Bren Simon
Comprehensive Cancer Center

Michelle Lin, MBA
VCU Massey Comprehensive Cancer Center

Rae Ann Paden, MPH
University of New Mexico
Comprehensive Cancer Center

Jennifer W. Pegher, MA
Association of American Cancer Institutes

John Pounardjian, MBA
Case Comprehensive Cancer Center

Suresh Ramalingam, MD
Winship Cancer Institute of Emory University

Matthew Vander Heiden, MD, PhD
Koch Institute for Integrative Cancer Research at MIT

Meeting App and Social Media

The agenda, presentations, exhibitor information, and attendees list are available on the meeting app. To access the app:

- Download “Cvent Events” from your mobile app store.
- Log in with the name and email used during registration.
- You will receive a 6-digit verification code. Enter your code and log in.
- Within the Cvent Events app, search for “2023 AACI/CCAF Annual Meeting” and download the meeting. The meeting app can also be accessed on your desktop at: https://cvent.me/N59VDY

Twitter: @AACICancer
Facebook: @AACICancer
LinkedIn: @AACI
Hashtag: #AACI2023
Wireless Network: AACI
Password: AACI2023!
Welcome to the 2023 AACI/CCAF Annual Meeting! This three-day meeting offers AACI members an opportunity to network with cancer center colleagues, national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges. This year’s conference also featured two pre-event sessions for new cancer center directors and those who are interested in improving diversity, equity, and inclusion efforts at their institutions.

I’d like to extend a warm welcome to our newest cancer center member, LSU-LCMC Health Cancer Center, and to the new members of AACI’s Board of Directors, Drs. Edward Chu, Raymond N. DuBois, and Yolanda Sanchez. I would like to express my deep appreciation to Dr. Caryn Lerman for her leadership of AACI over the last two and a half years. Dr. Lerman’s AACI presidential leadership diversity and development initiative has been a great success, and will continue with the second cohort in March of 2024. I’d also like to express AACI’s appreciation for outgoing board members, Drs. Roy A. Jensen and Cornelia Ulrich, and congratulate Dr. Joann B. Sweasy, AACI’s new vice president/president-elect.

We are pleased to recognize the research achievements of Dr. Patricia LoRusso with this year’s Distinguished Scientist Award. Dr. LoRusso will describe her personal journey as a clinical researcher. We will also present Dana Dornsife with the AACI Champion for Cures Award, recognizing her tireless work on behalf of the Lazarex Cancer Foundation. Ms. Dornsife is a generous supporter of community outreach and engagement efforts to increase access to cancer care and clinical trials in minority and disadvantaged communities. Dr. Amelie Ramirez will receive the AACI Cancer Health Equity Award to recognize her efforts to improve equity and diversity in cancer clinical trial recruitment, community outreach, and preventive cancer care.

This year’s meeting program features panel discussions on enhancing diversity at cancer centers; dismantling barriers to cancer care; and expanding the impact of global oncology. Additionally, AACI’s basic science cancer center members will share updates on their pioneering research, and AACI Vice President/President-elect Dr. Robert A. Winn will provide an overview of his new presidential initiative.

The program was jointly formulated by AACI and the Cancer Center Administrators Forum (CCAF). I am thankful for the hard work and expertise of the 2023 AACI/CCAF Annual Meeting Program Committee and to Dr. Primo N. Lara, who chaired the committee. I also extend my deep gratitude to the AACI staff who helped make this meeting possible.

Sincerely,

Jennifer W. Pegher
Executive Director
Agenda

All sessions will be held in the Grand Ballroom, except where indicated.

Sunday, October 1

11:00 am  Registration and Exhibits Open  
            Grand Foyer

1:00 pm   Welcome and AACI Business Meeting

Dr. Caryn Lerman  
USC Norris Comprehensive Cancer Center

Jennifer W. Pegher  
Association of American Cancer Institutes

David M. Gosky  
The Ohio State University Comprehensive Cancer Center – The James

Dr. Matthew Huesser  
Sidney Kimmel Cancer Center at Jefferson Health

Dr. Primo N. Lara, Jr.  
UC Davis Comprehensive Cancer Center

1:45 pm   Keynote: The Best Cancer is the Cancer That Never Happens

Dr. Philip E. Castle, director of the Division of Cancer Prevention (DCP) at the National Cancer Institute, will provide an update on DCP initiatives with a focus on the benefits and challenges of cancer screening, including detecting precancerous lesions in the era of minimally invasive tests like liquid biopsies.

Moderator: Dr. Primo N. Lara  
UC Davis Comprehensive Cancer Center

Dr. Philip E. Castle  
National Cancer Institute

2:45 pm   Networking Break

Supported by The Ohio State University Comprehensive Cancer Center – The James  
Grand Foyer
3:10 pm  **Executing Plans to Enhance Diversity: Results From a National Survey**

Attendees will hear results of a national survey of diversity, equity, and inclusion (DEI) leaders that assessed strategies and challenges in enhancing diversity at cancer centers, as well as recruitment strategies, DEI education and training, future plans, and other metrics.

**Dr. Christopher Li**  
*Fred Hutchinson Cancer Center*

3:30 pm  **The SCOTUS Affirmative Action Ruling: Gauging the Impact on Cancer Centers**

In handing down new restrictions on race-conscious admissions this past summer, the U.S. Supreme Court shined a bright light on criteria currently used at colleges and medical schools to determine who can attend. In this session, panelists will consider the impact of the court’s decision on cancer centers and efforts to increase minority accrual in clinical trials and diversify the oncology workforce.

**Moderator: Dr. Robert A. Winn**  
*VCU Massey Comprehensive Cancer Center*

**Dr. David Acosta**  
*Association of American Medical Colleges*

**Kevin D. Williams, Esq.**  
*National Institutes of Health*

4:00 pm  **Update on the NCI Cancer Centers Program**

Dr. Henry Ciolino will lead a discussion about the National Cancer Institute’s (NCI) goals for the national cancer research enterprise and provide updates on NCI funding at AACI cancer centers.

**Dr. Henry Ciolino**  
*National Cancer Institute*

5:00 pm  **ACCA (CCAF) Business Meeting** *(closed session)*  

Gallery Ballroom A
Agenda

5:00 pm 11th Annual AACI Physician Clinical Leadership Initiative (PCLI) Meeting: Bridging the Divide Between Cancer Centers and Cancer Service Lines

Optimal coordination of patient care between hospitals, clinics, infusion centers, pharmacies, and ancillary services is a hallmark of the nation’s top cancer centers. In this session, panelists will outline the functions of a cancer service line, how it is defined by the National Cancer Institute, and how service lines at their respective centers are organized, particularly in terms of governance and structure, financial arrangements, and metrics.

Moderator: Dr. Paula Fracasso
VCU Massey Comprehensive Cancer Center

Dr. Rondeep Brar
Stanford Cancer Center

Dr. Seungjean Chai
Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Dr. Andrew Chapman
Sidney Kimmel Cancer Center at Jefferson Health

6:00 – 7:30 pm Welcome Reception
Supported by Integra Connect
Grand Lawn (weather permitting) /Ballroom Foyer

Monday, October 2

7:00 am Breakfast
Gallery Ballroom

7:00 am AACI Cancer Center Directors Breakfast (invitation only)
Phillips

8:30 am AACI Presidential Initiative
AACI Vice President/President-elect Dr. Robert A. Winn will present plans for his presidential initiative, during which he aims to work with cancer centers, universities, and other stakeholders to develop a “roadmap” for inclusive excellence.

Dr. Robert Winn
VCU Massey Comprehensive Cancer Center
9:00 am  **Dismantling Barriers to Cancer Care**

Across the cancer care continuum, cancer centers and organizations face challenges in reaching underserved communities – particularly those coping with persistent poverty. Panelists will share how their institutions are addressing these challenges, from public health policy to screening, early detection, and clinical trial participation.

**Co-moderator: Dr. Kelvin Lee**  
*Indiana University Melvin and Bren Simon Comprehensive Cancer Center*

**Co-moderator: Rae Ann Paden**  
*University of New Mexico Comprehensive Cancer Center*

**Dr. Debra Friedman**  
*Vanderbilt-Ingram Cancer Center*

**Dr. Rian Hasson**  
*Dartmouth Cancer Center*

**Dr. Gary Puckrein**  
*National Minority Quality Forum*

10:00 am  **Exploring New Ways to Enhance Diversity at Cancer Centers**

For AACI’s member cancer centers, diversity, equity, and inclusion are key components in the push to accelerate progress against cancer. In this session, representatives from selected centers will describe how they are enhancing diversity, emphasizing specific strategies applicable to patients, leadership, staff, and associated partners, as well as initiatives to expand clinical trial access to all members of the community.

**Co-moderator: Dr. Hannah Hazard-Jenkins**  
*WVU Cancer Center*

**Co-moderator: John Pounardjian**  
*Case Comprehensive Cancer Center*

**Dr. Adebola A. Adedimeji**  
*Montefiore Einstein Comprehensive Cancer Center*

**Shiva Bidar-Sielaff**  
*University of Wisconsin Carbone Cancer Center*

**Dr. Lovoria Williams**  
*UK Markey Cancer Center*

11:00 am  **Break**

Grand Foyer
Agenda

**11:15 am**

**2023 AACI Distinguished Scientist Award**

The Making of a Clinical Researcher: A Personal Journey

Gallery Ballroom

**Moderator:** Dr. Joann B. Sweasy

*The University of Arizona Cancer Center*

**Dr. Patricia LoRusso**

*Yale Cancer Center, Yale School of Medicine*

---

**12:15 pm**

**Lunch and AACI Awards Presentation**

Gallery Ballroom

**2023 Cancer Health Equity Award**

Dr. Amelie Ramirez

*Mays Cancer Center at UT Health San Antonio MD Anderson*

**2023 AACI Champion for Cures Award**

Dana Dornsife

*Lazarex Cancer Foundation*

**2023 AACI Public Service Awards**

Senator Amy Klobuchar (D-MN)

Representative Neal Dunn (R-FL)

---

**1:15 pm**

**Networking and Dessert Break**

Supported by The Ohio State University Comprehensive Cancer Center – The James

Grand Foyer

---

**1:45 pm**

**Expanding the Impact of Global Oncology**

With about 65 percent of cancer deaths worldwide occurring in low- and middle-income countries (LMIC), controlling global cancer requires confronting cancer in these countries. To that end, a recent survey of NCI-Designated Cancer Centers found that about 90 percent of centers engage in global oncology activities. Panelists will describe the global oncology programs at their institutions, with particular focus on LMICs and the need for enhanced coordination and funding.

**Moderator:** Dr. Patrick Loehrer

*Indiana University Melvin and Bren Simon Comprehensive Cancer Center*

**Dr. Satish Gopal**

*National Cancer Institute*

**Dr. Stephen Kimani**

*Huntsman Cancer Institute, University of Utah*

**Dr. Martin Lajous**

*National Institute of Public Health (Instituto Nacional de Salud Pública)*

**Dr. Elias Melly**

*National Cancer Institute of Kenya*
2:00 pm  **AACI Government Relations Forum**  
(Session not CME accredited; pre-registration required)  
Hillwood  
The Government Relations Forum provides an opportunity for attendees to network and discuss timely public policy topics. The meeting will feature compelling speakers from government, consulting firms, and AACI cancer centers.

2:45 pm  **Research and Development at Basic Science Centers**  
AACI’s basic science center members focus on laboratory research and translate their findings to better cancer treatments. Directors from these centers will highlight innovative research discoveries that are accelerating progress against cancer.

**Moderator:** Dr. Matthew Vander Heiden  
*Koch Institute for Integrative Cancer Research at MIT*  
**Dr. Dario Altieri**  
*Ellen and Ronald Caplan Cancer Center of The Wistar Institute*  
**Dr. Rohit Bhargava**  
*Cancer Center at Illinois*  
**Dr. Karolina Palucka**  
*The Jackson Laboratory Cancer Center*  
**Dr. Ze’ev Ronai**  
*Sanford Burnham Prebys Medical Discovery Institute*

3:45 pm  **Break**  
Grand Foyer
Collaboration Fueling Innovation

This session will look at several key issues around the National Cancer Institute's Cancer Center Support Grant, including ways centers can more effectively collaborate; how consortium collaborations enhance the cancer center mission; the interconnectedness of cancer research training and education coordination, community outreach and engagement, and diversity, equity, and inclusion; and how all parties that interact with these groups can work together.

Moderator: Dr. Matthew Huesser
Sidney Kimmel Cancer Center at Jefferson Health

Dr. Wendy Law
Fred Hutchinson Cancer Center

Michelle Lin
VCU Massey Comprehensive Cancer Center

Rae Ann Paden
University of New Mexico Comprehensive Cancer Center

John Pounardjian
Case Comprehensive Cancer Center

Vendor Presentation: Triomics

Call for Collaboration: Building a ChatGPT for Oncology
(Session not CME accredited)

Hirshhorn

Large Language Models, such as OpenAI's ChatGPT, have taken the world by storm. However, their lack of understanding of clinical datasets has hindered their applications in clinical care and research. Against this backdrop, Triomics, in partnership with several leading cancer centers and Ci4CC, is spearheading the development of a specialized oncology-focused large language model. This model aims to assist the wider community by facilitating the use of data embedded in clinical notes for applications such as patient matching and data abstraction for EDC entry in clinical trials. Join this session to learn more about the collaboration, its structure, and how your cancer center can potentially participate and benefit.

Sarim Khan
Triomics

8:00 – 10:00 pm Hospitality
Supported by Florence
Tuesday, October 3

7:00 am  Breakfast
Gallery Ballroom

8:00 am  ARPA-H: A New Mechanism for Supporting Cancer Research
This session will provide an overview of the Advanced Research Projects Agency for Health (ARPA-H) and its potential for advancing innovative and transformative technologies in cancer research and care, including advancing the development of cancer drugs, biomarkers, vaccines, and multicancer early detection blood tests.
Ileana Hancu
Advanced Research Projects Agency for Health

8:30 am  Improving Cancer Center Interactions With Elected Officials and Federal Agencies
Cancer centers are continuously seeking ways to guide policy at the state, local, and federal levels. Panelists will describe policy areas of interest for cancer centers and what steps they are taking to educate policymakers and the public.
Co-moderator: Dr. Edward Chu
Montefiore Einstein Comprehensive Cancer Center

Co-moderator: Erik Fatemi
Cornerstone Government Affairs

Laura Bozell
Cornerstone Government Affairs

Laura Friedel
Tarplin, Downs & Young, LLC

Paul Kim
Kendall Square Policy Strategies, LLC

9:30 am  Break
Supported by The Ohio State University Comprehensive Cancer Center – The James Grand Foyer
9:45 am  **Clinical Trial Activation: Simple is Better**

Optimizing “time to activation” of clinical trial protocols, including implementing “just in time” activation mechanisms for trials in rare and uncommon tumors, can reduce clinical trial complexity and regulatory burden. Panelists will also consider the impact of extended trial activation on patient participation and clinical trial office staffing issues like retention and burnout.

**Co-moderator: Dr. Suresh Ramalingam**  
*Winship Cancer Institute of Emory University*

**Co-moderator: Michelle Lin**  
*VCU Massey Comprehensive Cancer Center*

**Alison Ivey**  
*University of Florida Health Cancer Center*

**Dr. Monica Joshi**  
*Penn State Cancer Institute*

**Mark Morrow**  
*University of Colorado Cancer Center*

10:45 am  **National Cancer Institute Director’s Report**

**Dr. Monica Bertagnolli**  
*National Cancer Institute*

11:45 am  **Adjourn**
Continuing Medical Education

Joint Providership Statement
Jointly provided by the American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI).

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research (AACR) and Association of American Cancer Institutes (AACI). AACR is accredited by the ACCME to provide continuing medical education (CME) for physicians.

Credit Designation
AACR has designated this live activity for a maximum of 13.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ (see Credit Designation above) for this live continuing medical education activity must complete the online CME Request for Credit Survey by Tuesday, October 31, 2023. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the conference website and via email. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.75 Medical Knowledge points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives
Despite enormous progress in the field, cancer continues to be a global public health challenge, accounting for one in every six deaths that occur around the world. In the United States alone, it is predicted that more than 600,000 people will die from some form of cancer in 2023, making it the second most common cause of death after heart disease.
With the quickening pace of discoveries in basic, translational, and clinical research, the battle against cancer is rapidly moving forward. This is due in large part to the advent of new technologies, such as liquid biopsies, and our growing knowledge about how to activate the immune system to develop new immunotherapies. However, understanding and combating cancer requires leadership armed with up-to-date information about advanced technology and proven methods for its implementation.

Planned Goals and Objectives for the Education
Researchers, physicians, and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to faculty and staff at their cancer centers. As part of the program’s learning objectives, all attendees should be able to describe and discuss:

- The National Cancer Institute’s (NCI) Division of Cancer Prevention initiatives, including the benefits and challenges of cancer screening, and how to detect precancerous lesions in the era of minimally invasive tests like liquid biopsies
- Optimal methods of delivering cancer care to patients in communities facing persistent poverty
- Research at basic science cancer centers
- Ways to diversify cancer centers’ faculty and workforce
- Compliance with current NCI Cancer Center Support Grant (CCSG) guidelines
- Global oncology programs with a focus on low- and middle-income countries
- The Advanced Research Projects Agency for Health (ARPA-H) and its potential for advancing innovative and transformative technologies in cancer research and care

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing health care products or services used by or on patients. All the relevant financial relationships for these individuals have been mitigated.

Americans With Disabilities Act
It is the policy of AACR and AACI not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please add a note on your registration form.

Acknowledgment of Financial or Other Support
This activity is supported by Professional Educational Grants and will be disclosed at the meeting.

Questions About CME?
Please contact the Office of CME at 215-440-9300 or cme@aacr.org.
2023 AACI Distinguished Scientist Award

Patricia LoRusso, DO
Yale Cancer Center
Yale School of Medicine

Patricia LoRusso, DO, is professor of medicine, associate center director for experimental therapeutics, and leader of the Early Phase Clinical Trials Division at Yale Cancer Center and Smilow Cancer Hospital. An internationally recognized expert in drug development and early-phase clinical investigation of novel therapies, Dr. LoRusso has contributed to crucial therapeutic breakthroughs for patients with cancer. She was integrally involved in the early development of more than two dozen anti-cancer agents that are now FDA approved and has pioneered trial designs that have led to more efficient clinical drug development strategies and enhanced accessibility for underrepresented populations.

Dr. LoRusso is currently president-elect of the American Association for Cancer Research (AACR) and chair of the New Agents Committee for Cancer Research UK; has served as chair and member of the National Cancer Institute (NCI)-CTEP Investigational Drug Steering Committee; and, by NCI invitation, serves as the current co-director of the Board of Scientific Council (BSC) (Clinical Sciences and Epidemiology). She has published over 300 peer-reviewed articles in highly respected journals of science and medicine, including the New England Journal of Medicine, Science Translational Medicine, Science Reports, Lancet Oncology, Clinical Cancer Research, and the Journal of Clinical Oncology.

Past AACI Distinguished Scientist honorees include Drs. Elizabeth M. Jaffee; Judy E. Garber; William G. Kaelin, Jr.; Douglas R. Lowy; Charles Perou; Carl June; James Allison; and Lewis Cantley.
Dana Dornsife, founder and chief mission and strategy officer of the Lazarex Cancer Foundation, is a devoted and generous supporter of community outreach and engagement efforts to increase access to cancer care and clinical trials in minority and disadvantaged communities in Los Angeles County. To close the cancer disparities gap, her transformative gifts created the Lazarex Impact Program to foster participation in clinical trials and Cancer Wellness Hubs.

The Cancer Wellness Hub initiative is a place-based, community-led, and culturally appropriate model of engagement which provides education and navigation services for cancer prevention, screening, and treatment, and removes transportation and financial barriers to increase access to clinical trials and optimal care. Specially-trained Neighborhood Health Ambassadors help ensure that community residents feel welcome and valued, and are treated with respect and dignity. The Lazarex Foundation also supports sites in San Francisco (UCSF) and in Philadelphia (Abramson Cancer Center), with national expansion planned in the future.

Dornsife participates in regular team meetings to optimize the success of the initiative. Her steadfast focus on improving the health and quality of life for diverse and underserved populations is unique among donors, and she "walks the walk" by participating actively at every level of the program, including development, implementation, and evaluation. She has also inspired others, including Amgen, which has become a key sponsor of this work.

The Champion for Cures Award was established as an annual award in 2018 to recognize philanthropic support of AACI cancer centers. Previous recipients are Pelotonia, Sidney and Caroline Kimmel, Phil and Peggy Knight, the Jon M. and Karen Huntsman family, and Richard and Susan Rogel.
2023 AACI Cancer Health Equity Award

Amelie Ramirez, DrPH, MPH
Mays Cancer Center at UT Health San Antonio MD Anderson

Amelie Ramirez, DrPH, MPH, chair and full professor of the Department of Population Health Sciences at UT Health San Antonio, leads a multidisciplinary team of public health researchers, data scientists, and communication specialists in addressing the cancer experience of Latinos. As leader of the community outreach and engagement (COE) team at the NCI-designated Mays Cancer Center (MCC), Dr. Ramirez has implemented changes that have improved equity and diversity in cancer clinical trial recruitment and directly involved the community in outreach, clinical research, and preventive cancer care.

Under her leadership, the COE has partnered with government organizations to implement community-facing programs and campaigns and led the development of the MCC’s first South Texas Cancer Survey, which uncovered the catchment area respondents’ exposure to cancer information, communication preferences, knowledge about cancer risk, and behaviors to reduce cancer risk.

Dr. Ramirez has directed over 100 research programs focused on human and organizational communication to reduce cancer health disparities affecting Latinos and other minority and underserved populations, including cancer risk factors, clinical trial recruitment, patient navigation, tobacco prevention, obesity prevention, and promotion of health equity system changes. Dr. Ramirez launched the Advancing the Science of Cancer in Latinos conference and has led three national, multisite research networks. Most recently, she founded a national Latino health equity communication and advocacy network, Salud America! (SA!), at UT Health San Antonio. SA! advances health equity for Latinos by communicating culturally relevant educational content and advocacy opportunities related to the themes of Healthy Families & Schools, Healthy Communities, and Healthy & Cohesive Cultures.

The AACI Cancer Health Equity Award was established in 2021. Previous recipients are Drs. Electra D. Paskett and Robert A. Winn.
Philip E. Castle, PhD, MPH
National Cancer Institute

Philip E. Castle, PhD, MPH, director of the Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI), will provide an update on DCP/NCI initiatives to support research on novel interventions for cancer prevention, cancer screening, and symptom management.

In addition to his role as is the director of the DCP, Dr. Castle is acting branch chief of the Cancer Prevention Fellowship Program in DCP, and senior, tenured investigator in the Division of Cancer Epidemiology and Genetics (DCEG) at the NCI. Previously, he was a tenured professor in the Department of Epidemiology and Population Health at Albert Einstein College of Medicine; chief scientific officer of the American Society for Clinical Pathology (ASCP); senior, tenured investigator and tenure-track investigator in DCEG/NCI; and a cancer prevention fellow in DCP/NCI. Dr. Castle received a PhD in biophysics and master’s degree in public health from the Johns Hopkins University.
Exhibitors

The Association of American Cancer Institutes (AACI) and the American Association for Cancer Research (AACR) express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

**Advarra**
Advarra advances the way clinical research is conducted: bringing life sciences companies, CROs, research sites, investigators, and academia together at the intersection of safety, technology, and collaboration. With trusted IRB and IBC review solutions, innovative technologies, experienced consultants, and deep-seated connections across the industry, Advarra provides integrated solutions that safeguard trial participants, empower clinical sites, ensure compliance, and optimize research performance. Advarra is advancing clinical trials to make them safer, smarter, and faster. Learn more about our cloud-based technology solutions, IBC and IRB services, Institutional Research Center of Excellence, and professional services. advarra.com

**Caris Life Sciences®**
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assess DNA, RNA, and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia, and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).

**ConcertAI**
ConcertAI is a leader in Real-World Evidence (RWE) and AI technology solutions for life sciences and health care. Our mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies. For more information, visit us at concertai.com.

**Deep 6 AI**
Deep 6 AI is the leader in precision research software, connecting all research stakeholders in an AI-powered, real-time, data-driven, collaborative ecosystem. Our Precision Matching software mines millions of patient records, including “unstructured” physician notes, to pinpoint eligible study patients in real time. Deep 6 AI eliminates months of manual data validation, to de-risk and accelerate clinical trials, because clinical trials should be a gatekeeper (accelerator), not a bottleneck to innovation. deep6ai
Exhibitors

ECG Management Consultants, a Siemens Healthineers Company
With knowledge and expertise built over the course of nearly 50 years, ECG is a national consulting firm that is leading health care forward. ECG offers a broad range of strategic, financial, operational, and technology-related consulting services to providers, building multidisciplinary teams to meet each client’s unique needs – from discrete operational issues to bigger-picture strategic and financial challenges. ECG is an industry leader, offering specialized expertise to hospitals, health systems, medical groups, academic medical centers, children’s hospitals, ambulatory surgery centers, and health care payers. Part of Siemens Healthineers’ global enterprise services practice, ECG’s subject matter experts deliver smart counsel and pragmatic solutions. ecgmc.com

Florence
Florence is a leading provider of Site Enablement solutions that streamline clinical research operations and improve collaboration among research sites, sponsors, and CROs. With a focus on driving innovation and enhancing the trial site experience through site enablement, Florence is committed to closing the cure acceleration gap and revolutionizing the clinical trial industry. florencehc.com

Huron
Our dedicated Cancer Practice builds upon the vast expertise of the Huron Consulting Group, a global organization that helps universities, hospitals, and research institutes drive growth, ignite innovation, and navigate constant change.

The Cancer Practice at Huron Consulting Group has worked with nearly all the NCI-designated and emerging cancer centers as well as many health systems. Our team is led by nationally recognized individuals who bring their 20-plus years of frontline experience to design tailored approaches and solutions that fit the specific goals of each client.

Huron has exceptional experience in clinical research, including leadership and organization, faculty issues, operations improvement, technology, business management, recruitment and retention, activation through closeout processes, enterprise and regional network development, as well as biotech partnerships. The Cancer Practice team spurs innovation and advances knowledge by enhancing clinical research operations, streamlining research administration, providing strategic planning guidance, and preparing for National Cancer Institute designation/redesignation. huronconsultinggroup.com

Idea Elan
Idea Elan provides Infinity Core management software for thousands of cores and labs worldwide. We have experience with over 150 different types of core facilities, such as Genomics, Proteomics, Microscopy, Flow Cytometry, and more.
We have implemented complex financial integrations with ERP systems such as SAP, Banner, Workday, Oracle, and PeopleSoft in comprehensive cancer centers. Infinity has over 25 modules that provide a comprehensive and scalable solution to all operational aspects of the cores and labs. Infinity customers have improved oversight of core services, increased productivity, and streamlined workflow across the Institution.

Moreover, we are an ISO 27001-certified organization for security and software development processes. ideelan.com

Inspirata, Inc.
Inspirata, Inc. helps patients fighting cancer—and the clinicians they trust—to make every moment matter. We are a Cancer Informatics company that offers several innovative software solutions leveraging scalable AI and NLP in the clinical trial and cancer registry spaces. Refined over more than a decade in collaboration with the National Cancer Institute (NCI) and used by hundreds of health care institutions globally, our proprietary NLP engine is at the heart of Nurse Navigator and Trial Navigator, our powerful clinical trial matching solutions, and our industry-leading E-Path suite of cancer registry automation solutions. inspirata.com

Integra Connect
Integra Connect is a value-based, precision medicine company that leads the industry in real-world data and analytics capabilities for oncology. With data from more than 11 million unique patient lives, decades of value-based care expertise, and sophisticated technologies, it enables specialty care providers, health systems, payers, and life sciences companies to improve patient outcomes, provider decision-making, business operations and performance, and clinical research for success under value-based care models. Since it was founded, Integra Connect has supported more than 5,000 providers, six payer organizations, and a multitude of life sciences companies in their efforts to advance value-based, precision medicine. integraconnect.com

Triomics
Triomics is a technology company that enables site staff to directly transfer data to/from EHRs, labs, medical devices, and other sources directly into both sponsors’ and investigators’ EDC of choice. In addition, Triomics provides a full-stack platform for sites to initiate and manage clinical studies, right from study activation, patient recruitment, and engagement to study finance; thus, helping sites save time and resources usually spent on double data entry, SDV with monitors, identifying patients, and managing study expenses. What’s more, Triomics provides its technology stack free of cost to the sites and always will. triomics.com
Verily
Verily is an Alphabet company that combines a data-driven, people-first approach to bring the promise of precision health to everyone, every day. Within Verily, the Clinical Studies Platforms organization provides solutions to generate the data and evidence needed to inform critical treatment and care decisions. This function evolved from Project Baseline, a multi-year research initiative, and is composed of leading experts in clinical science, RWD and RWE, technology, and user experience. The team delivers research-ready datasets that bring together a wide variety of different sources of health data to represent the longitudinal health journey of individuals. To do this, Verily focuses on understanding permissions, enabling traceability, and solving for markedly different data integrity and quality.

Our solutions bring together evidence generation, care delivery, and care management in a connected and reinforcing ecosystem built to advance precision health, connecting research participants with studies and offering tools to improve clinical research. This includes SignalPath, a new state-of-the-art clinical trial management system (CTMS) that was built by researchers, for researchers, to dramatically improve the ease, quality, efficiency, and profitability of trial execution. verily.com

Vitalief
Vitalief is a leading consulting company formed to address the dynamic needs of research and clinical trial organizations with groundbreaking consulting; flexible resourcing; adaptable managed services; and transformative learning and development services. Our innovative operating models ensure success within the new realities of research and clinical trials. Our solutions target high risk, high value, and high impact areas such as study activation, maximizing clinical trials office performance, and enhancing burdensome administrative processes with a dynamic reservoir of readily mobilized, skilled professionals. Our holistic approach delivers world-class expertise, efficient processes, and optimized infrastructure that result in better, more efficient clinical trials. vitalief.com

WCG
WCG is a global leader of solutions that measurably improve and accelerate clinical research. With our unmatched expertise, data intelligence, and purpose-built technology, we partner with research sites to enhance efficiency, speed start-up timelines, reduce administrative burden, and improve financial results. Visit to learn more: wgc.com

Yunu, Inc.
Yunu provides medical research technology and services to life sciences companies and clinical research environments that perform precision imaging assessments. Yunu’s aim is to ensure breakthrough therapies are accessible to everyone by unifying medical imaging insights and connecting clinical communities. With thousands of clinical trials relying on the platform each day, Yunu is delivering a new standard of oncology trial management. yunu.io
Acknowledgment of Commercial Support

The Association of American Cancer Institutes (AACI) and the American Association for Cancer Research (AACR) express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- Novartis
- Varian

Acknowledgment of Programmatic Support

AACI gratefully acknowledges the following organizations for providing program and exhibit support:

- Admininformatics
- Advarra
- Caris Life Sciences®
- ConcertAI
- Deep 6 AI
- ECG Management Consultants, a Siemens Healthineers Company
- Florence
- Huron
- Idea Elan
- Inspirata, Inc.
- Integra Connect
- The Ohio State University Comprehensive Cancer Center – The James
- Triomics
- VCU Massey Comprehensive Cancer Center
- Verily Life Sciences
- Vitalief
- WCG
- YUNU, Inc.

Support as of September 25, 2023
<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Relationships</th>
<th>Type</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acosta</td>
<td>David</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Adelejemji</td>
<td>Adebola</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Altieri</td>
<td>Dario</td>
<td>Gladius Therapeutics</td>
<td>S, IC</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bertagnolli</td>
<td>Monica</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Bhargava</td>
<td>Rohit</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Bidar-Sielaff</td>
<td>Shiva</td>
<td>Latino Academy for Workforce Development, Madison Community Foundation, Latino Health Council of Dane County, Madison College, Share the Health</td>
<td>FO, FO, FO, FO, FO</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bozell</td>
<td>Laura</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Brar</td>
<td>Rondeep</td>
<td>Alexion Pharmaceuticals, Inc., Apellis Pharmaceuticals</td>
<td>IC, IC</td>
<td>Speaker</td>
</tr>
<tr>
<td>Castle</td>
<td>Philip</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Chai</td>
<td>Seungjean</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Chapman</td>
<td>Andrew</td>
<td>Roche Health Solutions Inc.</td>
<td>IC</td>
<td>Speaker</td>
</tr>
<tr>
<td>Chu</td>
<td>Edward</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Ciolino</td>
<td>Henry</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Fatemi</td>
<td>Erik</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Fracasso</td>
<td>Paula</td>
<td>Adaptimmune LLC</td>
<td>S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Friedel</td>
<td>Laura</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Friedman</td>
<td>Debra</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Gopal</td>
<td>Satish</td>
<td>No Relationships</td>
<td>E</td>
<td>Speaker</td>
</tr>
<tr>
<td>Hancu</td>
<td>Ileana</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Hasson</td>
<td>Rian</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Hazard-Jenkins</td>
<td>Hannah</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Huesser</td>
<td>Matthew</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Ivey</td>
<td>Alison</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Joshi</td>
<td>Monika</td>
<td>Seattle Genetics, Inc., AstraZeneca Pharmaceuticals LP</td>
<td>IC, GC</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kim</td>
<td>Paul</td>
<td>AstraZeneca, Sanofi, National Organization for Rare Disorders</td>
<td>IC, IC, IC</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kimani</td>
<td>Stephen</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Lajous</td>
<td>Martin</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Lara</td>
<td>Primo</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Law</td>
<td>Wendy</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
</tbody>
</table>
In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing health care products or services used by or on patients.

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Relationships</th>
<th>Type</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee</td>
<td>Kelvin</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Li</td>
<td>Christopher</td>
<td>No Relationships</td>
<td>E</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lin</td>
<td>Michelle</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Loehrer</td>
<td>Patrick</td>
<td>No Relationships</td>
<td>E</td>
<td>Speaker</td>
</tr>
<tr>
<td>LoRusso</td>
<td>Patricia</td>
<td>STCube Pharmaceuticals, imCheck, Qualigen, Relay Therapeutics, Actuate Therapeutics, Seagen Inc., Zentalis Pharmaceuticals, Compass BADX, Stemline Therapeutics Inc., Mersana Therapeutics, BAXX Therapeutics, Roivant Sciences, Kyowa Kirin Pharmaceutical Development, Inc, Scenic Biotech, Molecular Templates, ABL Bio, Mekanist, NeuroTrials, QED Therapeutics, Kineta, I-Mab</td>
<td>IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC</td>
<td>Speaker</td>
</tr>
<tr>
<td>Melly</td>
<td>Elias</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Morrow</td>
<td>Mark</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Paden</td>
<td>Rae Ann</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Palucka</td>
<td>Karolina</td>
<td>Cue BioPharma, Guardian Bio, Cue BioPharma</td>
<td>IC, IC, S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Pegher</td>
<td>Jennifer</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td></td>
</tr>
<tr>
<td>Pounardjian</td>
<td>John</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Puckrein</td>
<td>Gary</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Ramalingam</td>
<td>Suresh</td>
<td>American Cancer Society, Bristol Myers Squibb, Amgen, Emory University</td>
<td>IC, IC, IC, E</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Ronai</td>
<td>Ze'ev</td>
<td>Pangea BioMed, Pangea BioMed</td>
<td>IC, SO</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sweasy</td>
<td>Joann</td>
<td>Yale University School of Medicine, Center for Clinical and Translational Science, University of Illinois at Chicago, Cancer Institute, University of Pittsburgh, Yale University School of Medicine</td>
<td>OIP, IC, IC, IC</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vander Heiden</td>
<td>Matthew</td>
<td>auron therapeutics, iTeos Therapeutics, Droia, Agios Pharmaceuticals, Inc., Sage Therapeutics, Inc.</td>
<td>IC, IC, IC, IC</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Williams</td>
<td>Kevin</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Williams</td>
<td>Lovoria</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Winn</td>
<td>Robert</td>
<td>LUNGevity Foundation, Genentech USA, Inc., American Cancer Society</td>
<td>IC, IC, IC</td>
<td>Speaker</td>
</tr>
</tbody>
</table>

All of the relevant financial relationships listed for these individuals have been mitigated.
## CME-Approved Sessions Worksheet

<table>
<thead>
<tr>
<th>Date</th>
<th>Time (eastern)</th>
<th>Session Title</th>
<th>Approved Credits</th>
<th>Credits Claimed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sunday 10/1/2023</strong></td>
<td></td>
<td><strong>Keynote — The Best Cancer is the Cancer That Never Happens</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:45 – 2:45 pm</td>
<td><strong>Executing Plans to Enhance Diversity: Results from a National Survey</strong></td>
<td>0.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3:10 – 3:30 pm</td>
<td><strong>The SCOTUS Affirmative Action Ruling: Gauging the Impact on Cancer Centers</strong></td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3:30 – 4:00 pm</td>
<td><strong>Update on the NCI Cancer Centers Program</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4:00 – 5:00 pm</td>
<td><strong>11th Annual AACI PCLI Meeting: Bridging the Divide Between Cancer Centers</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td><strong>Maximum Approved Credits for 10/1/2023</strong></td>
<td></td>
<td></td>
<td>3.75</td>
<td>Total:</td>
</tr>
<tr>
<td><strong>Monday 10/2/2023</strong></td>
<td></td>
<td><strong>AACI Presidential Initiative Update</strong></td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:30 – 9:00 am</td>
<td><strong>Dismantling Barriers to Cancer Care</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9:00 – 10:00 am</td>
<td><strong>Exploring New Ways to Enhance Diversity at Cancer Centers</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:00 – 11:00 am</td>
<td><strong>AACI Distinguished Scientist — The Making of a Clinical Researcher: A Personal Journey</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11:15 am – 12:15 pm</td>
<td><strong>Expanding the Impact of Global Oncology</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1:45 – 2:45 pm</td>
<td><strong>Research and Development at Basic Science Centers</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:45 – 3:45 pm</td>
<td><strong>Collaboration Fueling Innovation</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td><strong>Maximum Approved Credits for 10/2/2023</strong></td>
<td></td>
<td></td>
<td>6.5</td>
<td>Total:</td>
</tr>
<tr>
<td><strong>Tuesday 10/3/2023</strong></td>
<td></td>
<td><strong>ARPA-H: A New Mechanism for Supporting Cancer Research</strong></td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:00 – 8:30 am</td>
<td><strong>Improving Cancer Center Interactions With Elected Officials and Federal Agencies</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:30 – 9:30 am</td>
<td><strong>Clinical Trial Activation: Simple is Better</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9:45 – 10:45 am</td>
<td><strong>National Cancer Institute Director’s Report</strong></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td><strong>Maximum Approved Credits for 10/3/2023</strong></td>
<td></td>
<td></td>
<td>3.5</td>
<td>Total:</td>
</tr>
<tr>
<td><strong>Maximum CME Credits Approved</strong></td>
<td></td>
<td></td>
<td>13.75</td>
<td>Total:</td>
</tr>
</tbody>
</table>
Cancer care is complex, research is complicated.

At Integra Connect, our focus is simple: make value-based, precision oncology a reality.

Integra Connect offers oncology-specific solutions to improve care quality and research, while also reducing costs of care.

We transform data into knowledge with:

- Information from industry-leading specialty care data,
- Insights from powerful AI and analytics solutions, and
- Intelligence from unprecedented experience and expertise

Let’s connect and bring transformational outcomes to your cancer center.

www.integraconnect.com
The Ohio State University
Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute

_is a proud sponsor of the_  

2023
AACI and CCAF
Annual Meeting

The James

[THE OHIO STATE UNIVERSITY]
COMPREHENSIVE CANCER CENTER

cancer.osu.edu
Clinical data is vital for research, enabling accurate patient-study matching and informing EDC/eCRF responses. However, lack of standardization and interoperability, along with crucial information hidden in clinical notes, impedes the development of automated systems, leading to labor-intensive manual procedures like chart reviews and double data entry from EHR to EDC.

Triomics leads in solving these problems, employing a solution that harnesses commonly adopted data standards and AI systems, such as language models. Our technology transforms manual tasks like eligibility chart reviews and EDC data entry from EHRs into efficient, automated processes, resulting in time and effort savings of over 80%.

Learn more about us at: www.triomics.com
SAVE THE DATES

2024 AACI Leadership Diversity and Development Workshop
March 11-13, 2024
Loews Chicago O’Hare Hotel
Rosemont, IL

2024 AACI/AACR Hill Day
May 16, 2024
Washington, DC

16th Annual AACI CRI Meeting
June 24-26, 2024
Loews Chicago O’Hare Hotel
Rosemont, IL

2024 AACI/CCAF Annual Meeting
October 20-22, 2024
Loews Chicago Hotel
Chicago, IL

17th Annual AACI CRI Meeting
June 23-25, 2025
Loews Chicago O’Hare Hotel
Rosemont, IL

2025 AACI/CCAF Annual Meeting
October 19-21, 2025
Salamander Washington DC
All-In-One Researcher Management

- Research Data Management
- Training Programs
- Publications
- Customize your tools on Grant Types: P30, P50, T32,...

We value your decade-long trust in us managing your cancer research document workflows.

Now, it’s your turn to design the future of how sponsors collaborate with you through technology.

Join the Site Enablement League – an exclusive alliance of 60+ research trailblazers. Collaborate, create, and lead the future of research, putting sites first.

Ask us how.

info@florencehc.com
Celebrating the Huron Cancer Center Team's 10 Years of Service to the NCI Community

Ten years ago this October, Huron founded the first consultancy dedicated to Cancer Centers. Since then, we have advised approximately 90% of NCI-designated Cancer Centers, many emerging Centers, universities, and systems across the country. Our favorite phrase is, “We couldn’t have done it without you.”

Our team of former NCI administrators, scientists, grant writers, and clinical research professionals have decades of experience. As a result, we can use our frontline and consulting expertise to support your changing needs. In commemorating our years of service, we want to thank AACI for supporting us and look forward to the years ahead.

Contact: bginsburg@hcg.com

Our services include:

- CCSG readiness assessment, strategy, and preparations
- Strategic planning
- Clinical trials organization, optimization, and networks
- Consortia and partnerships
- Service line
- Leadership and organization
- New leader support
- SPOREs, CTSAs, P and U grants

SAVE THE DATE
December 7-9, 2023
Richmond, VA

PRESENTED BY

B EYOND DEFINITION

IN PARTNERSHIP WITH
Yunu transforms clinical trial imaging workflow - solving today’s biggest challenges for cancer centers, CROs, core labs, and sponsors.

- Simple administration
- Pristine imaging workflow
- Protocol standardization
- Proactive communication
- Rapid patient turn-around times
- Optimized imaging assessments
- Scalable staffing
- Audit-readiness

You’ve always known trial imaging workflows were broken, let us show you a new way forward.

CONTACT US
yunu.io info@yunu.io